BIOMAT Database Logo BIOMAT Database Logo

Daily versus weekly azithromycin in cystic fibrosis patients. 2007

J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Department of Medicine and Infectious Diseases, University of Queensland, Mater Adult Hospital, South Brisbane, 4101 Queensland, Australia. jmccorma@mater.org.au

Four randomised, placebo-controlled trials have previously documented the clinical benefits of azithromycin (AZM) in cystic fibrosis (CF) patients. The present study examined whether the beneficial effect of AZM is equivalent when administered daily or weekly. A double-blind, randomised study was carried out in 208 CF patients aged 6-58 yrs who were assigned to AZM either 250 mg daily (n = 103) or 1,200 mg weekly (n = 105) for 6 months, with assessments at baseline and at 1, 3, 6 and 7 months. Patients were taken from five adult and children CF centres in South-east Queensland, Australia. Equivalence was demonstrated between the two groups (daily versus weekly) with respect to improvements in lung function (forced expiratory volume in one second and forced vital capacity), C-reactive protein, days spent in hospital, admission rates and nutrition (body mass index, z-scores) using 95% confidence intervals with a tolerance interval of +/-10%. In patients aged <18 yrs the daily group had significantly better improvements in z-scores for height and weight after 6 months. In children, a nutritional advantage for daily administration was found. Gastro-intestinal adverse effects were more common with weekly therapy. Apart from these findings, daily and weekly administered azithromycin demonstrated similar outcomes for cystic fibrosis patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009894 Opportunistic Infections An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression. Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Daily versus three-times-weekly azithromycin in Chinese patients with non-cystic fibrosis bronchiectasis: protocol for a prospective, open-label and randomised controlled trial.
July 2022, BMJ open,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
November 2008, Respiratory medicine,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients.
January 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients.
May 1996, The Journal of antimicrobial chemotherapy,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Azithromycin in cystic fibrosis.
April 2005, The European respiratory journal,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Azithromycin use in patients with cystic fibrosis.
June 2015, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Azithromycin and cystic fibrosis.
August 2022, Archives of disease in childhood,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Azithromycin for cystic fibrosis.
November 2004, The European respiratory journal,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
[Azithromycin therapy in cystic fibrosis].
March 2004, Medicina clinica,
J McCormack, and S Bell, and S Senini, and K Walmsley, and K Patel, and C Wainwright, and D Serisier, and M Harris, and S Bowler
Long term azithromycin therapy in patients with cystic fibrosis.
January 2016, The Turkish journal of pediatrics,
Copied contents to your clipboard!